Your browser doesn't support javascript.
loading
Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.
Iwayanagi, Yuki; Igawa, Tomoyuki; Maeda, Atsuhiko; Haraya, Kenta; Wada, Naoko A; Shibahara, Norihito; Ohmine, Ken; Nambu, Takeru; Nakamura, Genki; Mimoto, Futa; Katada, Hitoshi; Ito, Shunsuke; Tachibana, Tatsuhiko; Jishage, Kou-ichi; Hattori, Kunihiro.
Affiliation
  • Iwayanagi Y; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Igawa T; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan igawatmy@chugai-pharm.co.jp.
  • Maeda A; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Haraya K; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Wada NA; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Shibahara N; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Ohmine K; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Nambu T; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Nakamura G; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Mimoto F; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Katada H; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Ito S; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Tachibana T; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Jishage K; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
  • Hattori K; Research Division, Chugai Pharmaceutical Co. Ltd., Tokyo 103-8324, Japan.
J Immunol ; 195(7): 3198-205, 2015 Oct 01.
Article in En | MEDLINE | ID: mdl-26320252
ABSTRACT
Fc engineering can modulate the Fc-FcγR interaction and thus enhance the potency of Abs that target membrane-bound Ags, but it has not been applied to Abs that target soluble Ags. In this study, we revealed a previously unknown function of inhibitory FcγRII in vivo and, using an Ab that binds to Ag pH dependently, demonstrated that the function can be exploited to target soluble Ag. Because pH-dependent Ab dissociates Ag in acidic endosome, its Ag clearance from circulation reflects the cellular uptake rate of Ag/Ab complexes. In vivo studies showed that FcγR but not neonatal FcR contributes to Ag clearance by the pH-dependent Ab, and when Fc binding to mouse FcγRII and III was increased, Ag clearance was markedly accelerated in wild-type mice and FcR γ-chain knockout mice, but the effect was diminished in FcγRII knockout mice. This demonstrates that mouse FcγRII efficiently promotes Ab uptake into the cell and its subsequent recycling back to the cell surface. Furthermore, when a human IgG1 Fc variant with selectively increased binding to human FcγRIIb was tested in human FcγRIIb transgenic mice, Ag clearance was accelerated without compromising the Ab half-life. Taken together, inhibitory FcγRIIb was found to play a prominent role in the cellular uptake of monomeric Ag/Ab immune complexes in vivo, and when the Fc of a pH-dependent Ab was engineered to selectively enhance human FcγRIIb binding, the Ab could accelerate soluble Ag clearance from circulation. We assume such a function would enhance the therapeutic potency of Abs that target soluble Ags.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin G / Receptors, IgG / Antigen-Antibody Complex / Antigen-Antibody Reactions / Antigens Limits: Animals / Humans Language: En Journal: J Immunol Year: 2015 Document type: Article Affiliation country: Japón

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunoglobulin G / Receptors, IgG / Antigen-Antibody Complex / Antigen-Antibody Reactions / Antigens Limits: Animals / Humans Language: En Journal: J Immunol Year: 2015 Document type: Article Affiliation country: Japón